{"filings":[{"id":95541,"accession_number":"0001193125-26-203913","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Damora Therapeutics CFO Lori Firmani to depart May 1; Brian Burkavage appointed principal financial officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Effective May 1, 2026, Lori Firmani will cease serving as CFO of Damora Therapeutics.","Firmani receives lump-sum salary continuation, prorated bonus, $6K HSA, and full equity acceleration.","Brian Burkavage, current SVP Finance, appointed principal financial and accounting officer effective May 1.","Burkavage previously SVP Finance and CAO at IO Biotech; CPA with 11 years at Ernst & Young."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95540,"accession_number":"0001193125-26-163909","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Damora Therapeutics dismisses EY Denmark auditor, appoints EY US","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee dismissed EY Denmark on April 17, 2026; EY US appointed same day.","No disagreements or reportable events occurred in FY 2024 or 2025 or the subsequent interim period.","EY Denmark's 2024 report included a going-concern explanatory paragraph.","Company provided EY Denmark with disclosures; EY Denmark's letter to SEC filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108682,"accession_number":"0001193125-26-118699","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Damora Therapeutics appoints Jennifer Jarrett as CEO, adds two directors, names chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jennifer Jarrett appointed President and CEO, effective March 30, 2026; also joins board.","Three directors (Munshi, Goldfischer, Dallas) resigned March 23; not due to disagreements.","New directors: Cameron Turtle (CEO, Spyre Therapeutics) and Mike Landsittel (ex-CFO, Blueprint Medicines).","Peter Harwin named Chairman of the Board.","Jarrett receives $695k base salary, 55% target bonus, 500k RSUs and 1.5M stock options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108687,"accession_number":"0001193125-26-099404","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["2.02","5.03","7.01","9.01"],"status":"ready","headline":"Galecto rebrands as Damora Therapeutics (DMRA); $535M cash; DMR-001 IND mid-2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name changed from Galecto to Damora Therapeutics; trades on Nasdaq as DMRA from March 10, 2026.","Preliminary cash and cash equivalents ~$535M as of Feb 28, 2026, including ~$316M from Feb 2026 public offering.","DMR-001 (anti-mutCALR antibody) IND/CTA on track for mid-2026; proof-of-concept data expected mid-2027.","DMR-002 IND/CTA planned for H2 2026; DMR-003 IND/CTA in 2027.","Acquisition of privately held Damora closed Nov 2025 with ~$285M private investment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108686,"accession_number":"0001193125-26-046817","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Galecto raises $295.9M in equity offering; funds Phase 3 of DMR-001","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 14,473,685 shares at $19.00 each; underwriters' option for 2,171,052 additional shares exercised in full.","Net proceeds of approximately $295.9M after underwriting discounts and expenses.","Proceeds intended to fund operations into Phase 3 development of DMR-001.","Underwriting agreement with Jefferies LLC and Leerink Partners LLC; closing expected February 12, 2026.","Offering was made under an automatic shelf registration statement on Form S-3 (File No. 333-293343)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108685,"accession_number":"0001193125-26-043741","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["5.02","5.03","5.07","8.01","9.01"],"status":"ready","headline":"Galecto CEO departs; authorized shares increased to 500M; outstanding shares jump to 43.6M after preferred conversion","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Hans T. Schambye departs effective Feb 10, 2026; COO Sherwin Sattarzadeh appointed interim principal executive officer.","Shareholders approve increase in authorized common shares from 300M to 500M, plus Cayman Islands redomestication.","Automatic conversion of Series C Preferred yields ~42M new shares; total outstanding rises from ~1.6M to ~43.6M.","Shareholders also approve 2026 Equity Incentive Plan and Employee Stock Purchase Plan.","Separation agreement for Schambye includes lump-sum base salary continuation, pro-rated bonus, and full equity acceleration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108684,"accession_number":"0001193125-26-009812","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Galecto furnishes corporate slide deck for J.P. Morgan Healthcare Conference; no new material disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed under Item 7.01 with a corporate presentation (January 2026) as Exhibit 99.1.","No specific financial, pipeline, or operational numbers were included in the exhibit text provided.","Presentation is for meetings at the 44th Annual J.P. Morgan Healthcare Conference starting Jan 12, 2026.","Investors cannot derive new material facts from the limited text available."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108683,"accession_number":"0001193125-26-003490","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["3.02","5.02","9.01"],"status":"ready","headline":"Galecto appoints Sherwin Sattarzadeh as COO; issues warrant to Paramora","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sherwin Sattarzadeh appointed COO effective Jan 5, 2026; base salary $540,000, target bonus 40%.","Initial equity grant includes 190,376 RSUs and options for 444,209 shares vesting over four years.","Issued warrant to Paramora for 628,302 shares at $23.01 per share under Paragon Option Agreement.","Severance provisions: 12 months' salary (18 months if within Change in Control Period) plus accelerated vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125129,"accession_number":"0001193125-25-312912","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K/A","filed_at":"2025-12-09T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Galecto corrects Series C Preferred Stock authorization from 43,855 to 43,882 shares","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Filed Certificate of Correction on Dec 5, 2025 to fix inadvertent error in Series C Preferred Stock designation.","Authorized shares revised to 43,882 from incorrectly stated 43,855; no other terms changed.","Amendment amends 8-K originally filed Nov 10, 2025; restated certificate attached as Exhibit 3.3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125130,"accession_number":"0001193125-25-273342","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["1.01","5.03","2.01","3.02","5.02","7.01","9.01"],"status":"ready","headline":"Galecto acquires Damora, raises ~$285M PIPE, appoints Fairmount-affiliated directors","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Galecto acquired Damora Therapeutics; issued 265,309 common shares, 16,366 Series B and 4,241 Series C preferred shares to Damora stockholders.","Concurrent PIPE of ~$285M via sale of 39,641 Series C preferred shares; closing expected Nov 12, 2025.","Board replaced: Anne Prener, David Shapiro, Amy Wechsler resigned; Peter Harwin, Chris Cain, Julianne Bruno (Fairmount) appointed.","Executive retention bonuses: CEO (DKK 2,173,800 target), CFO ($112,500), GC ($161,160); CFO salary increased to $375,000.","Series B & C preferred are non-voting, convertible 1:1,000 into common, subject to stockholder approval and ownership caps."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159772,"accession_number":"0000950170-25-088168","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Galecto stockholders approve director elections, preferred stock conversion, and auditor ratification","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Carl Goldfischer and David Shapiro elected as Class II directors with 219,253 and 226,360 votes for; 435,515 broker non-votes.","Preferred stock conversion approved: 226,407 for, 15,099 against, 800 abstain; 435,515 broker non-votes.","Ratification of EY as auditor approved: 660,974 for, 16,319 against, 528 abstain; no broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194807,"accession_number":"0000950170-24-114481","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Galecto appoints Dr. Amy Wechsler to Board of Directors effective October 11, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded to seven members; Wechsler appointed as Class I director with term through 2027 annual meeting.","Wechsler is board-certified in dermatology and psychiatry and serves on the Bausch Health board.","She holds an M.D. from Cornell University Medical College and an M.B.A. from Columbia Business School (2024).","Wechsler is independent under Nasdaq standards and will receive standard non-employee director compensation and equity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194806,"accession_number":"0000950170-24-113091","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["1.01","2.01","3.02","5.02","5.03","7.01","9.01"],"status":"ready","headline":"Galecto acquires global rights to BRM-1420 dual ENL-YEATS/FLT3 inhibitor for AML","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Galecto issued 62,594 common shares and 160.562 Series A convertible preferred shares (convertible into 160,562 common) to Bridge Medicines.","BRM-1420 is a novel dual ENL-YEATS and FLT3 inhibitor targeting multiple genetic subsets of acute myeloid leukemia (AML).","Carl Goldfischer, Galecto's Chairman, also serves as Executive Chairman of Bridge Medicines (related-party transaction).","Pro forma impact: cash reduced by $2.68M; total consideration valued at stock issuance; assumes liabilities.","Stockholder approval required for conversion of preferred shares; Bridge Medicines restricted from selling shares for 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211099,"accession_number":"0000950170-24-107580","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2024-09-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Galecto regains Nasdaq minimum bid price compliance; matter closed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq Staff letter confirming compliance with Rule 5550(a)(2) based on bid price >= $1.00 from Aug 30 to Sep 13, 2024.","The deficiency notice is now closed; no further action required on this matter.","Shares continue trading on Nasdaq Capital Market under ticker GLTO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211098,"accession_number":"0000950170-24-105533","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2024-09-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Galecto completes 1-for-25 reverse stock split; post-split shares at 1,248,266","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split effective August 29, 2024; every 25 shares converted to 1 share.","Computershare confirms total outstanding shares post-split: 1,248,266.","Fractional shares resulting from the reverse split were rounded up to the nearest whole share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211097,"accession_number":"0000950170-24-103957","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Galecto effectuates 1-for-25 reverse stock split effective August 29, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse split at June 20 special meeting; board set ratio at 1-for-25.","Every 25 pre-split shares converted into 1 share; fractional shares rounded up to whole share.","Outstanding stock options and equity plans proportionately adjusted; trading symbol GLTO unchanged.","New CUSIP number is 36322Q 206; split effective after market close on August 29, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229615,"accession_number":"0000950170-24-076186","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Galecto shareholders approve reverse stock split and elect Anne Prener to board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Director Anne Prener elected with 10,651,770 for, 711,618 withheld; 5,840,793 broker non-votes.","Reverse stock split approved (ratio 1:4 to 1:25, board to decide within one year): 15,283,182 for, 1,830,713 against.","Ratification of EY as auditor for FY2024 passed with 16,927,703 for, 197,148 against.","Total shares entitled to vote: 27,112,697; 17,204,181 present or represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248141,"accession_number":"0000950170-24-036391","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Galecto transfers to Nasdaq Capital Market; granted 180-day extension for bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Transferred listing from Nasdaq Global Select to Nasdaq Capital Market effective March 22, 2024.","Received 180-day extension until September 22, 2024 to regain $1.00 minimum bid price compliance.","Company had failed to meet bid price requirement by March 25, 2024 compliance date.","GLTO continues trading under same symbol; reverse stock split is under consideration.","If not compliant by September 22, Nasdaq may delist; company could appeal to hearings panel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}